gms | German Medical Science

10. Kongress für Infektionskrankheiten und Tropenmedizin (KIT 2010)

Deutsche Gesellschaft für Infektiologie,
Deutsche AIDS-Gesellschaft,
Deutsche Gesellschaft für Tropenmedizin und Internationale Gesundheit,
Paul-Ehrlich-Gesellschaft für Chemotherapie

23.06. - 26.06.2010, Köln

Nevirapine (NVP) as a component of antiretroviral regiment is effective and well tolerated over a ten year period of treatment (528 weeks) in a german private doctor's office

Eine Nevirapin(NVP)-haltige antiretrovirale Therapie ist langfristig effektiv und gut verträglich – 10-Jahres-Daten (528 Wochen) einer deutschen HIV-Schwerpunktpraxis

Meeting Abstract

  • G. Knecht - Infektiologikum, Frankfurt, Germany
  • A. Bodtlaender - Infektiologikum, Frankfurt, Germany
  • A. Mueller - Infektiologikum, Frankfurt, Germany
  • A. Carlebach - Infektiologikum, Frankfurt, Germany
  • T. Lutz - Infektiologikum, Frankfurt, Germany
  • P. Gute - Infektiologikum, Frankfurt, Germany

10. Kongress für Infektionskrankheiten und Tropenmedizin (KIT 2010). Köln, 23.-26.06.2010. Düsseldorf: German Medical Science GMS Publishing House; 2010. DocP113

doi: 10.3205/10kit168, urn:nbn:de:0183-10kit1684

Published: June 2, 2010

© 2010 Knecht et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( You are free: to Share – to copy, distribute and transmit the work, provided the original author and source are credited.



Introduction: Nevirapine (NVP) is now over ten years available for HIV infected patients. For us it was of particular interest to document how long a treatment with Nevirapine is possible and how the data for the long-term-tolerance look like.

Methods: In this monocentre, retrospective data base analysis 57 patients were identified on an antiretroviral regiment with Nevirapine and a variable backbone over a ten years period of treatment.

Data of viral load and CD4 cell counts from baseline till week 528 were analysed. Also the results of blood lipids (cholesterol, triglycerides and the liver enzyms (AST, ALT,GGT).

The demographics showed that 82% of participants were male and 89% were caucasian. The middle age was 52 years. The mean CD4 lymphocyte count at baseline was 229 (14%) cells/µl and the mean viral load was 8150 copies/ml. At week 528 the mean CD4 lymphocyte count was 592 (29%) and 90% of all patients had less than 50 HIV copies/ml.

Results: No significant change of cholesterol and triglycerides was seen in the patients. No liver toxicity was shown regarding the liver enzymes and clinical outcomes.

Conclusions: NVP-based regimens are virologically and immunologically effective. It appears to be well tolerated over such a long time with fewer side effects.